Proportion of patients with cessation of vomiting · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) probably leads to higher proportion of patients with cessation of vomiting compared with placebo (moderate certainty).
1 finding from 1 review
Revisit rate · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) showed no clear difference in revisit rate compared with placebo (low certainty).
1 finding from 1 review
Pruritus · patients with chronic kidney disease (CKD) pruritus
1 finding from 1 review
Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Ondansetron changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
rolapitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
Intervention not reported
Ondansetron vs control · women having spinal anaesthesia for caesarean section
The intervention may leads to lower ondansetron vs control (low certainty).
1 finding from 1 review
Ondansetron VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review